Ken Griffin Calliditas Therapeutics Ab Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$17.65 - $41.41 $56,479 - $132,512	-3,200 Reduced 33.33%	6,400 $249,000
Q1 2024 May 15, 2024	SELL	$20.04 - $25.66 $8,016 - $10,264	-400 Reduced 4.0%	9,600 $201,000
Q4 2023 Feb 14, 2024	BUY	$15.79 - $28.99 $71,055 - $130,455	4,500 Added 81.82%	10,000 $257,000
Q3 2023 Nov 14, 2023	BUY	$15.68 - $20.38 $6,272 - $8,152	400 Added 7.84%	5,500 $100,000
Q2 2023 Aug 14, 2023	SELL	$15.7 - $25.61 $124,030 - $202,319	-7,900 Reduced 60.77%	5,100 $80,000
Q1 2023 May 15, 2023	BUY	$16.8 - $25.24 $152,880 - $229,684	9,100 Added 233.33%	13,000 $311,000
Q4 2022 Feb 14, 2023	BUY	$11.5 - $19.6 $44,850 - $76,440	3,900 New	3,900 $66,000

20.3K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.